Vistagen to Present at Stifel 2022 Healthcare Conference

Rhea-AI Summary

Vistagen Therapeutics (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on CNS disorders, announced that CEO Shawn Singh will present at the Stifel 2022 Healthcare Conference in New York on November 15, 2022, at 9:10 a.m. Eastern Time. The company is developing innovative therapeutics for anxiety and depression, including investigational drugs PH94B and PH10, which offer a novel rapid-onset mechanism. Investors can arrange one-on-one meetings by contacting the conference coordinator.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Stifel 2022 Healthcare Conference taking place in New York on November 15 and 16, 2022.

Stifel 2022 Healthcare Conference Details
Presentation Date and Time: Tuesday, November 15, 2022 at 9:10 a.m. Eastern Time
Location: New York, New York

Investors interested in arranging a one-on-one meeting during the conference should contact the Stifel 2022 Healthcare Conference coordinator.

About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression – one mind at a time. Connect at www.Vistagen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005640/en/

Investors:

Mark Flather

Vice President, Investor Relations

(650) 577-3617

mflather@vistagen.com

Media:

Nate Hitchings

SKDK

nhitchings@skdknick.com

Source: Vistagen

FAQ

When will Vistagen present at the Stifel 2022 Healthcare Conference?

Vistagen will present on November 15, 2022, at 9:10 a.m. Eastern Time.

Where is the Stifel 2022 Healthcare Conference taking place?

The conference is taking place in New York, New York.

What is Vistagen Therapeutics focusing on?

Vistagen is focused on developing therapeutics for anxiety, depression, and other CNS disorders.

What are the names of Vistagen's clinical-stage candidates?

Vistagen's clinical-stage candidates include PH94B and PH10.

What is the mechanism of action for Vistagen's drugs?

Vistagen's drugs activate chemosensory neurons in the nasal passages, impacting the olfactory-amygdala neural circuits without systemic uptake.